EU gives nod to Lilly, Novartis drugs; Lundbeck offers up Lexapro alternative;

 @FiercePharma: Philly judge lets J&J CEO Alex Gorsky off the hook; he can't be compelled to testify in Risperdal case. More | Follow @FiercePharma

> An advisory committee in the European Union is recommending approval of Eli Lilly's ($LLY) Cialis 5 mg for daily use to treat signs and symptoms of benign prostatic hyperplasia (BPH). Release

> EU regulators also on Friday gave recommendations to two Novartis ($NVS) drugs, Galvus and Eucreas, to be used in combo with other treatments for Type 2 diabetes. Story 

> Seattle is being hard hit by Dendreon's decision to cut 600 employees, with 145 of those coming from the Northwest city. Story 

> Thermo Fisher Scientific is inaugurating a new molecular biology center of excellence in Vilnius, Lithuania, targeting the Eastern European market. Story 

> Sanofi ($SNY) has again partnered with the Global Alliance for TB Drug Development to look for new treatments. Item 

> ViroPharma is rolling out Plenadren in Europe for the treatment of adrenal insufficiency. Item 

> Danish drugmaker Lundbeck has filed an application with EU regulators for a new generation of antidepressant, vortioxetine, as it deals with the loss of patent on its popular antidepressant, Lexapro. Story

Medical Device News

 @FierceMedDev: Devicemaker NeuroMetrix has 6 months to get its Nasdaq stock price up to the minimum bid. Release | Follow @FierceMedDev

 @MarkHFierce: After months of bad defibrillator news, St. Jude hits something better: A CE mark for a neurostim migraine treatment. Story | Follow @MarkHFierce

 @DamianFierce: Medtronic is back in court, facing a suit alleging that its pain pump left a man paralyzed. News | Follow @DamianFierce

> Less than $1M later, Washington device startup eyes FDA submission. More

> Australia bets on medical device R&D with new fund. Article

Biotech News

 @FierceBiotech: In case you missed it yesterday, check out our 2012 Fierce 15 slideshow from BioPharm America 2012. Slideshow | Follow @FierceBiotech

 @JohnCFierce: Progenics in Tarrytown gets out the ax (again), cuts research, lops staffers. Release | Follow @JohnCFierce

 @RyanMFierce: New pharma-academic tie-up. Bristol-Myers Squibb tapped academics at Vanderbilt on Parkinson's drug research. More | Follow @RyanMFierce

> MorphoSys zeroes in on partner for blockbuster hopeful against arthritis. News

> Vivus: EU regulators expected to balk on obesity drug. Report

> Google VC group eyes biotech bets with $1B purse. Story

And Finally... Amgen ($AMGN) says the FDA has approved Prolia for treating bone mass loss in men with osteoporosis who are at high risk for breaking bones. Release